Nathan Kow, MD
Urogynecology and Reconstructive Pelvic Surgery · Orlando, FLNPI 1114125051
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.2%), education and food and beverage — rather than concentrated in one kind of arrangement. Coloplast accounts for 80.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $34,128 and has fallen 52.0% since, to $16,386 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $384.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$93K
- Medtronic$7K
- Axonics, Inc.$7K
- Boston Scientific$6K
- Intuitive Surgical$1K
- Hologic Sales And Service, LLC$900
- plus $429 from 7 others
Across 1 payment — averaging $472.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$473
What the payments were for
- Consulting fees$64,02055%
- Speaking & faculty fees$4,8384%
- Travel & lodging$8,6547%
- Food & beverage$12,37511%
- Education$26,12723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 136 | $92,991 |
| Medtronic(2 entities) | 57 | $7,348 |
| Axonics, Inc. | 46 | $7,328 |
| Boston Scientific | 37 | $5,910 |
| Intuitive Surgical | 11 | $1,106 |
| Hologic Sales And Service, LLC | 2 | $900 |
| AbbVie(2 entities) | 6 | $196 |
| Pacira Pharmaceuticals Incorporated | 1 | $100 |
| Astellas Pharma US Inc | 2 | $40 |
| Asensus Surgical, Inc. | 1 | $31 |
| Coopersurgical, Inc. | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$87,674
- INTERSTIM$5,583
- Axonics$5,213
- SOLYX$3,808
- TITAN$1,470
- Bulkamid$1,054
- Axonics r-SNM System$1,021
- Da Vinci Surgical System$831
- GENERAL - THERAPIES$517
- Solyx SIS System$499
- FEMALE INCONTINENCE$289
- Advantage System$126
- Orilissa$110
- SPEEDICATH$108
- EXPAREL$100
How this compares
$116,013 in reported general payments places this provider in the 95th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
See all urogynecology and reconstructive pelvic surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 159 | $93,871 |
| GemtesaVibegron | 29 | $27,168 |
| PremarinEstrogens, Conjugated | 14 | $5,897 |
| Estradiol | 53 | $3,790 |
| ImvexxyEstradiol | 14 | $2,967 |
| Methenamine Hippurate | 31 | $2,462 |
| Oxybutynin Chloride ErOxybutynin Chloride | 107 | $1,535 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 56 | $718 |
| Bethanechol Chloride | 24 | $554 |
| Ibuprofen | 107 | $369 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 76 | $277 |
| Tramadol Hcl | 85 | $207 |
| Cephalexin | 27 | $187 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $146 |
| Tamsulosin Hcl | 16 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $40 | $93,871159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
Other urogynecology and reconstructive pelvic surgery in Orlando
- Charbel SalamonOrlando$100K
- Andrea AvondstondtOrlando$16K
- Lindsay KissaneOrlando$8K
- Rebeccah BriskinOrlando$4K
- Amir ShariatiCoconut Creek$106K
- Allison WymanTampa$69K
- Nicole SzellLargo$54K
- Jose Lazaro WeissOviedo$28K
- Paul PettitJacksonville$27K
- Arash RahiCoconut Creek$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.